The global Non-Small Cell Lung Cancer (NSCLC) therapeutics market size stood at around USD 18.14 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Non-small cell lung cancer accounts for 80%-85% of the total cases of lung cancer globally and this significant share of non-small cell lung cancer has driven the majority of key market leaders to focus on constant innovation of advanced therapeutics and increasing the efficacy of the existing therapeutics. This is also due to the status of lung cancer as one of the most commonly occurring cancers in the world and its contribution to a significant number of deaths worldwide.
An increasing number of diagnoses of non-small cell lung cancer and the increasing awareness in the countries of the developed and developing markets are also contributing towards the non-small cell lung cancer therapeutics market growth. This, coupled with increasing investments by major players in research and development activities, and the inclusion of non-small cell cancer therapeutics in pipelines of major market players are also boosting the market growth globally.
Some of the other factors which are also contributing to the non-small cell lung cancer therapeutics market growth are the increase in the proportion of the smoking population and exposure to toxins such as asbestos. Greater adoption and increasing demand for targeted therapies, which is considered to be the foundation of precision medicine due to the increasing R&D initiatives and also due to its sophistication in targeting of cancerous cells, is one of the most prominent leading to factors that are responsible for the growth of the global NSCLC market.
Major NSCLC Market by Cancer Type
Based on cancer type, the global non-small cell lung cancer therapeutics market segments include adenocarcinoma, squamous cell carcinoma and large cell carcinoma.